A post-authorization study to assess the safety and efficacy of Fanhdi (Double-inactivated human anti-hemophilic factor) in subjects with Von Willebrand disease (PostAuthorization Study with Fanhdi in VWD patient)

ENCePP Code of conduct

No

Data sources

• Data sources (types):
  Administrative healthcare records (e.g., claims)

  Disease registry

  Other
• Data sources (types), other:
  Prospective patient-based data collection, Prescription event monitoring

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  No